We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

178 hedge funds and large institutions have $1.96B invested in Rocket Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 74 increasing their positions, 50 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $5.17M | Put options by funds: $3.15M

48% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 50

1.56% less ownership

Funds ownership: 102.06% → 100.51% (-1.6%)

4% less funds holding

Funds holding: 186 → 178 (-8)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

21% less capital invested

Capital invested by funds: $2.48B → $1.96B (-$522M)

22% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 27

Holders
178
Holders Change
-8
Holders Change %
-4.3%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
21
Increased
74
Reduced
50
Closed
27
Calls
$5.17M
Puts
$3.15M
Net Calls
+$2.02M
Net Calls Change
-$15.1M

Top Buyers

1
WP
Woodline Partners
California
+$12.9M
2
EC
EcoR1 Capital
California
+$11.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$10.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$8M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$7.9M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$34M
2
State Street
State Street
Massachusetts
-$32.5M
3
LGM
Logos Global Management
California
-$21.8M
4
PA
Perceptive Advisors
New York
-$12.7M
5
CAM
Cormorant Asset Management
Massachusetts
-$8.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
51
Ikarian Capital
Texas
$4.24M -$2.3M -100,000 -34%
GC
52
GMT Capital
Georgia
$4.05M -$962K -41,900 -18%
TD Asset Management
53
TD Asset Management
Ontario, Canada
$3.84M +$528K +23,000 +15%
SF
54
Synovus Financial
Georgia
$3.62M +$1.94M +84,679 +102%
N
55
Nuveen
North Carolina
$3.61M +$176K +7,680 +5%
NLVP
56
New Leaf Venture Partners
New York
$3.24M +$746K +32,464 +27%
Neuberger Berman Group
57
Neuberger Berman Group
New York
$3.24M +$826K +35,961 +31%
William Blair & Company
58
William Blair & Company
Illinois
$3.07M -$105K -4,566 -3%
Manulife (Manufacturers Life Insurance)
59
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.01M +$610K +26,556 +23%
Barclays
60
Barclays
United Kingdom
$2.82M +$581K +25,292 +24%
Jane Street
61
Jane Street
New York
$2.81M +$3M +130,538 New
Nordea Investment Management
62
Nordea Investment Management
Sweden
$2.76M -$496K -21,584 -14%
Swiss National Bank
63
Swiss National Bank
Switzerland
$2.68M – – –
UBS AM
64
UBS AM
Illinois
$2.54M +$1.2M +52,282 +79%
Rafferty Asset Management
65
Rafferty Asset Management
New York
$2.53M -$4.86M -211,398 -64%
Millennium Management
66
Millennium Management
New York
$2.27M +$2.42M +105,325 New
NIM
67
NEOS Investment Management
Connecticut
$2.21M +$1.04M +45,247 +79%
Prudential Financial
68
Prudential Financial
New Jersey
$2.21M -$1.35M -58,925 -36%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$2.18M +$114K +4,958 +5%
Renaissance Technologies
70
Renaissance Technologies
New York
$2.14M +$2.29M +99,574 New
HCA
71
Harbor Capital Advisors
Illinois
$2.09M +$361K +15,708 +19%
DekaBank Deutsche Girozentrale
72
DekaBank Deutsche Girozentrale
Germany
$1.92M – – –
Rockefeller Capital Management
73
Rockefeller Capital Management
New York
$1.87M +$34.7K +1,511 +2%
RHJA
74
Rice Hall James & Associates
California
$1.62M +$66.5K +2,895 +4%
Thrivent Financial for Lutherans
75
Thrivent Financial for Lutherans
Minnesota
$1.62M -$73.7K -3,210 -4%
1 2
3
4 5

RCKT Hedge Fund Activity: Q2 2024 in Review

178 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2024, worth a combined $1.96B — down 21% from $2.48B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RCKT and 21 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 74 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $12.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $34M sold.

  • 178 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2024, down from 186 in Q1 2024.
  • Funds reported $1.96B of Rocket Pharmaceuticals stock for Q2 2024, down 21% quarter-over-quarter.
  • 21 funds opened new Rocket Pharmaceuticals positions in Q2 2024 and 27 closed out, a net change of -6 holders.
  • The largest Rocket Pharmaceuticals buyer in Q2 2024 was Woodline Partners, an estimated $12.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2024 was Avoro Capital Advisors, an estimated $34M sold.

Based on aggregated 13F filings for Q2 2024.